Actos and Ethinyl Estradiol and Norelgestromin
Determining the interaction of Actos and Ethinyl Estradiol and Norelgestromin and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.
Professional:Coadministration with another thiazolidinedione, troglitazone, has been shown to decrease the plasma concentrations of contraceptive hormones. The proposed mechanism is induction of hormone metabolism via CYP450 3A4. In 15 healthy female subjects, troglitazone (60 mg once daily for 3 weeks) decreased the mean steady-state peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of ethinyl estradiol and norethindrone (35 mcg-1 mg) by approximately 30% each compared to administration of the contraceptive alone. Four subjects experienced breakthrough bleeding during the cycle with troglitazone. There are no data on the use of contraceptive hormones with pioglitazone. Because pioglitazone may be a weak inducer of CYP450 3A4, product labeling recommends additional caution in women requiring contraception. However, some studies have reported no significant effect of pioglitazone on CYP450 3A4. Rosiglitazone labeling states that the drug given in a dosage of 4 mg twice daily had no clinically relevant effect on the pharmacokinetics of oral contraceptives (ethinyl estradiol and norethindrone). Intrauterine systems are unlikely to be significantly affected because of their local action.
- Loi CM, Stern R, Koup JR, Vassos AB, Knowlton P, Sedman AJ "Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent." J Clin Pharmacol 39 (1999): 410-7
- "Product Information. Avandia (rosiglitazone)" SmithKline Beecham, Philadelphia, PA.
- Nowak SN, Edwards DJ, Clarke A, Anderson GD, Jaber LA "Pioglitazone: effect on CYP3A4 activity." J Clin Pharmacol 42 (2002): 1299-302
- Glazer NB, Cheatham WW "Thiazolidinediones for type 2 diabetes - No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4." Br Med J 322 (2001): 235-6
- "Product Information. Actos (pioglitazone)" Takeda Pharmaceuticals America, Lincolnshire, IL.
Generic Name: ethinyl estradiol / norelgestromin
Brand name: Xulane, Ortho Evra
Synonyms: Ethinyl estradiol and norelgestromin (transdermal)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Actos-Ethinyl estradiol and norelgestromin transdermal
- Actos-Ethinyl estradiol and norethindrone
- Actos-Ethinyl estradiol and norethindrone birth control
- Actos-Ethinyl Estradiol and Norethindrone Chewable Tabs & Ferrous Fumarate Tabs
- Actos-Ethinyl estradiol and norethindrone HRT
- Actos-Ethinyl Estradiol and Norethindrone Tablets
- Ethinyl Estradiol and Norelgestromin-Acuflex
- Ethinyl Estradiol and Norelgestromin-Acular
- Ethinyl Estradiol and Norelgestromin-Acular eent
- Ethinyl Estradiol and Norelgestromin-Acular LS
- Ethinyl Estradiol and Norelgestromin-Acular PF
- Ethinyl Estradiol and Norelgestromin-Acunivive 15 Injection System